Tilmanocept
Head And Neck Cancer
Anna CrucetaOtherPhase 4 / ApprovedDormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 95/ 100
Competitive context
142 Active assets in the Head And Neck Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nepenthe Instituto Nacional de Cancer, Brazil | Phase 4 | BB |
Cis-Diamminedichloroplatinum Ii ImmunityBio, Inc. | Phase 3 | BB |
Lidocaine Instituto Nacional de Cancer, Brazil | Phase 3 | BB |
Carboplatin Rapa Therapeutics LLC | Phase 3 | BB |
Epirubicin Thomas Jefferson University | Phase 3 | BB |
View all 49 →
Same molecule, other indications
Tilmanocept is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →